SATELLOS BIOSCIENCE INC (MSLE) Stock Price & Overview
NASDAQ:MSLE • CA80401L8033
Current stock price
The current stock price of MSLE is 5.86 USD. Today MSLE is down by -2.98%. In the past month the price decreased by -50.77%.
MSLE Key Statistics
- Market Cap
- 120.892M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.12
- Dividend Yield
- N/A
MSLE Stock Performance
MSLE Stock Chart
MSLE Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to MSLE.
MSLE Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MSLE. MSLE has a great financial health rating, but its profitability evaluates not so good.
MSLE Earnings
MSLE Forecast & Estimates
9 analysts have analysed MSLE and the average price target is 19.95 USD. This implies a price increase of 240.38% is expected in the next year compared to the current price of 5.86.
MSLE Groups
Sector & Classification
MSLE Financial Highlights
Over the last trailing twelve months MSLE reported a non-GAAP Earnings per Share(EPS) of -2.12. The EPS increased by 23.04% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -58.46% | ||
| ROE | -64.49% | ||
| Debt/Equity | 0 |
MSLE Ownership
MSLE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.1 | 380.121B | ||
| AMGN | AMGEN INC | 15.28 | 190.443B | ||
| GILD | GILEAD SCIENCES INC | 15.78 | 174.171B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.65 | 113.617B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.15 | 82.171B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.69 | 43.596B | ||
| INSM | INSMED INC | N/A | 35.536B | ||
| NTRA | NATERA INC | N/A | 28.801B | ||
| BIIB | BIOGEN INC | 11.07 | 26.972B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.86 | 24.995B | ||
| MRNA | MODERNA INC | N/A | 19.759B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.548B | ||
| INCY | INCYTE CORP | 12.46 | 18.767B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About MSLE
Company Profile
Satellos Bioscience Inc is a CA-based company operating in Biotechnology industry. The company is headquartered in Toronto, Ontario and currently employs 14 full-time employees. The company went IPO on 2006-12-01. Satellos Bioscience Inc. is a Canada-based clinical-stage drug development company. The firm is focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, the Company has developed SAT-3247, a first-of-its-kind, orally administered small molecule drug designed to address deficits in muscle repair and regeneration. SAT-3247 targets AAK1, a key protein that has identified as capable of replacing the signal normally provided by dystrophin in muscle stem cells to effect repair and regeneration. The company is also leveraging its proprietary discovery platform MyoReGenX to identify additional muscle diseases or injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and represent future clinical development opportunities. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process.
Company Info
IPO: 2006-12-01
SATELLOS BIOSCIENCE INC
200 Bay Street, Suite 2800
TORONTO ONTARIO CA
Employees: 14
Phone: 16476601780
SATELLOS BIOSCIENCE INC / MSLE FAQ
What does SATELLOS BIOSCIENCE INC do?
Satellos Bioscience Inc is a CA-based company operating in Biotechnology industry. The company is headquartered in Toronto, Ontario and currently employs 14 full-time employees. The company went IPO on 2006-12-01. Satellos Bioscience Inc. is a Canada-based clinical-stage drug development company. The firm is focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, the Company has developed SAT-3247, a first-of-its-kind, orally administered small molecule drug designed to address deficits in muscle repair and regeneration. SAT-3247 targets AAK1, a key protein that has identified as capable of replacing the signal normally provided by dystrophin in muscle stem cells to effect repair and regeneration. The company is also leveraging its proprietary discovery platform MyoReGenX to identify additional muscle diseases or injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and represent future clinical development opportunities. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process.
Can you provide the latest stock price for SATELLOS BIOSCIENCE INC?
The current stock price of MSLE is 5.86 USD. The price decreased by -2.98% in the last trading session.
Does MSLE stock pay dividends?
MSLE does not pay a dividend.
How is the ChartMill rating for SATELLOS BIOSCIENCE INC?
MSLE has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Is SATELLOS BIOSCIENCE INC (MSLE) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on MSLE.
What is the ownership structure of SATELLOS BIOSCIENCE INC (MSLE)?
You can find the ownership structure of SATELLOS BIOSCIENCE INC (MSLE) on the Ownership tab.